D1306
Debrisoquine sulfate
powder, ≥98% (TLC)
동의어(들):
3,4-Dihydro-2(1H)-isoquinolinecarboximidamide, Debrisoquin sulfate, Ro 5-33071
로그인조직 및 계약 가격 보기
모든 사진(2)
About This Item
Linear Formula:
C20H26N6 · H2SO4
CAS Number:
Molecular Weight:
448.54
EC Number:
MDL number:
UNSPSC 코드:
12352204
PubChem Substance ID:
NACRES:
NA.32
추천 제품
제품명
Debrisoquine sulfate,
분석
≥98% (TLC)
Quality Level
양식
powder
mp
285 °C
solubility
H2O: 20 mg/mL (with heat)
저장 온도
room temp
SMILES string
OS(O)(=O)=O.NC(=N)N1CCc2ccccc2C1.NC(=N)N3CCc4ccccc4C3
InChI
1S/2C10H13N3.H2O4S/c2*11-10(12)13-6-5-8-3-1-2-4-9(8)7-13;1-5(2,3)4/h2*1-4H,5-7H2,(H3,11,12);(H2,1,2,3,4)
InChI key
CAYGYVYWRIHZCQ-UHFFFAOYSA-N
유전자 정보
human ... SLC6A2(6530)
유사한 제품을 찾으십니까? 방문 제품 비교 안내
생화학적/생리학적 작용
Debrisoquine is an anti-hypertensive agent. It is metabolized by cytochrome P4502D6.
기질
A substrate for cytochrome P450 CYP2D6; an indicator for genetic polymorphism in cytochrome P450.
신호어
Warning
유해 및 위험 성명서
예방조치 성명서
Hazard Classifications
Acute Tox. 4 Oral
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
개인 보호 장비
dust mask type N95 (US), Eyeshields, Gloves
N E Caporaso et al.
Environmental health perspectives, 98, 101-105 (1992-11-01)
Debrisoquine is an antihypertensive drug that is metabolized by cytochrome P4502D6. Deficient metabolism is inherited as an autosomal recessive condition. We previously reported in a case-control study that extensive metabolizers of debrisoquine were at greater risk of lung cancer compared
E Scarr et al.
Progress in neuro-psychopharmacology & biological psychiatry, 15(2), 297-301 (1991-01-01)
1. Studies were carried out on three monoamine oxidase (MAO) inhibitors, two of which, debrisoquine and para- hydroxyphenelzine, are purported to be peripheral inhibitors and one, phenelzine, is a peripherally acting inhibitor, which has been included for comparitive purposes. 2.
The debrisoquine metabolic phenotype and DNA-based assays: implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype.
Caporaso N E, et al.
Environmental Health Perspectives, 98, 101-105 (1992)
B Clement et al.
Biochemical pharmacology, 46(12), 2249-2267 (1993-12-14)
The microsomal N-hydroxylation of the strongly basic guanidinium group (debrisoquine) to N-hydroxyguanidine (N-hydroxydebrisoquine) and the retroreduction of the N-hydroxyguanidine are demonstrated for the first time. The reduction of the N-hydroxyguanidine by liver homogenates and hepatocytes is catalysed by a microsomal
J W Ho et al.
Analytical biochemistry, 203(2), 348-351 (1992-06-01)
Debrisoquine and sparteine are prototype substrates of a genetic deficiency in cytochrome P450-dependent drug metabolism. Sensitive assays of in vitro oxidation of sparteine and debrisoquine are required for evaluation of this polymorphism. The activities were measured by quantitative analysis of
문서
Phase I biotransformation reactions increase drug compound polarity, mainly occurring in hepatic circulation.
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.